Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026Business Wire · Oct 8, 2026
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD StudyBusiness Wire · Aug 24, 2026
Precision BioSciences: Promising HBV Editing EvidenceSeeking Alpha · Aug 18, 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateGuruFocus · Aug 6, 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire · Aug 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026Business Wire · Jul 31, 2026Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.80 | -$1.26 | Miss |
| May 5, 2026 | -$0.27 | -$0.75 | Miss |
| Mar 12, 2026 | -$0.21 | $1.05 | Beat |
| Nov 3, 2025 | -$0.31 | -$1.84 | Miss |
| Aug 7, 2025 | -$0.09 | -$2.13 | Miss |
| May 15, 2025 | -$0.43 | -$2.21 | Miss |